Protalix BioTherapeutics, Inc. financial data

Symbol
PLX on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
2 University Plaza, Suite 100, Hackensack, NJ
Fiscal year end
December 31
Former names
ORTHODONTIX INC (to 2/22/2007), EMBASSY ACQUISITION CORP (to 3/31/1998)
Latest financial report
10-Q - Q1 2025 - May 9, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 186 % +6.46%
Quick Ratio 59.5 % +20.2%
Debt-to-equity 101 % -32.2%
Return On Equity 10.5 % -46.3%
Return On Assets 5.2 % -33.5%
Operating Margin 7.74 % -42.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78M shares +6.82%
Common Stock, Shares, Outstanding 75.9M shares +3.97%
Entity Public Float 82M USD -41.1%
Common Stock, Value, Issued 76K USD +4.11%
Weighted Average Number of Shares Outstanding, Basic 76.6M shares +4.9%
Weighted Average Number of Shares Outstanding, Diluted 76.6M shares +4.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 59.8M USD +0.18%
Cost of Revenue 29.9M USD +32.9%
Research and Development Expense 13.6M USD -4.07%
Operating Income (Loss) 4.63M USD -42.6%
Nonoperating Income (Expense) 527K USD +236%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 5.16M USD -23.8%
Income Tax Expense (Benefit) 1.25M USD +18.1%
Net Income (Loss) Attributable to Parent 3.91M USD -42.9%
Earnings Per Share, Basic 0.05 USD/shares -54.5%
Earnings Per Share, Diluted 0.05 USD/shares -37.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.5M USD -28.5%
Accounts Receivable, after Allowance for Credit Loss, Current 4.68M USD +24.4%
Inventory, Net 19.5M USD -12.7%
Other Assets, Current 1.59M USD +95.8%
Assets, Current 60.5M USD -19.7%
Deferred Income Tax Assets, Net 2.97M USD -8.08%
Property, Plant and Equipment, Net 4.73M USD -1.17%
Operating Lease, Right-of-Use Asset 5.23M USD -11.1%
Assets 73.9M USD -17.7%
Accounts Payable, Current 19.6M USD +4.47%
Employee-related Liabilities, Current 1.35M USD -46.2%
Accrued Liabilities, Current 9.35M USD +10.6%
Contract with Customer, Liability, Current 12.7M USD
Liabilities, Current 24.3M USD -55.6%
Operating Lease, Liability, Noncurrent 3.81M USD -15.3%
Liabilities 28.7M USD -52.2%
Retained Earnings (Accumulated Deficit) -378M USD +0.83%
Stockholders' Equity Attributable to Parent 45.2M USD +51.8%
Liabilities and Equity 73.9M USD -17.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.06M USD -221%
Net Cash Provided by (Used in) Financing Activities 5.08M USD
Net Cash Provided by (Used in) Investing Activities -312K USD +48.5%
Common Stock, Shares Authorized 185M shares 0%
Common Stock, Shares, Issued 75.9M shares +3.97%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -302K USD -108%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.5M USD -28.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 766K USD -28.9%
Deferred Tax Assets, Valuation Allowance 50.7M USD -1.85%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 5.53M USD -8.36%
Depreciation 346K USD +7.45%
Payments to Acquire Property, Plant, and Equipment 306K USD -48.8%
Lessee, Operating Lease, Liability, to be Paid 7.87M USD -12.9%
Property, Plant and Equipment, Gross 40.3M USD +1.69%
Operating Lease, Liability, Current 1.43M USD -1.93%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.24M USD -11.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.5M USD +6.46%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Deferred Income Tax Expense (Benefit) 261K USD +18.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.34M USD -22%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.09M USD -3.56%
Deferred Tax Assets, Operating Loss Carryforwards 50M USD -2.83%
Current Income Tax Expense (Benefit) 164K USD +72.6%
Preferred Stock, Shares Authorized 100M shares
Unrecognized Tax Benefits 805K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.04M USD -0.38%
Deferred Tax Assets, Net of Valuation Allowance 2.86M USD -7.63%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares